BMS enters two immuno-oncology deals

Share this article:

Bristol-Myers Squibb has deepened its bets on immuno-oncology. The drugmaker announced Tuesday that it is testing its experimental PD-1 inhibitor nivolumab in combination with Incyte's oral dioscygenase-1 inhibitor, INCB24360.

The Phase I/II study will address multiple tumor types, which the companies said in a joint statement may include melanoma, non-small cell lung cancer, ovarian cancer and squamous cell carcinoma of the head and neck, among others.

BMS announced in April that it planned to complete its nivolumab rolling submission to the FDA for non-small cell lung cancer at the end of this year.

Tuesday's collaboration news also included Bristol Myers-Squibb's announcement that it was taking up with CytomX Therapeutics to develop “novel therapies against multiple immuno-oncology targets using CytomX's proprietary Probody Platform.” The companies explained in a joint statement that probodies are selectively activated antibodies which can spare healthy tissue.

The includes a $50 million upfront payment to CytomX and gives BMS exclusive rights to develop probodies for up to four oncology targets.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.